FDA.reportPublic FDA data

plasminogen, human-tvmh 68.8 MG Injection [Ryplazim]

RxCUI
2557210
RxNorm name
plasminogen, human-tvmh 68.8 MG Injection [Ryplazim]
Display name
plasminogen, human-tvmh 68.8 MG Injection [Ryplazim]
Full name
plasminogen, human-tvmh 68.8 MG Injection [Ryplazim]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:00

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125659Ryplazimplasminogen, human-tvmh351(a)Rx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
5c5a00ca-d662-46e6-b9ac-a07e9cfcc0a8Ryplazim 68.8 MG Injection [PSN] · plasminogen, human-tvmh 68.8 MG Injection [Ryplazim] [SBD] · Ryplazim 68.8 MG Injection [SY]38These highlights do not include all the information needed to use RYPLAZIM ® safely and effectively. See full prescribing information for RYPLAZIM. RYPLAZIM ® (plasminogen, human-tvmh) lyophilized powder for reconstitution, for intravenous use Initial U.S. Approval: 202120250915